IL17A and atrial fibrillation: Interleukin-17A levels are also elevated in patients with AF (17), and treatment with anti-IL-17A monoclonal antibody markedly suppressed AF development in a rat model of sterile pericarditis, concomitantly reducing atrial inflammation and fibrosis (18).